AKU:NSD-Akumin Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 3.19

Change

-0.02 (-0.47)%

Market Cap

USD 0.23B

Volume

0.01M

Avg Analyst Target

USD 3.50 (+9.89%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Akumin Inc. provides outpatient diagnostic imaging services in the United States. Its centers offer physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and reduce unnecessary invasive procedures. The company provides various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, and other diagnostic or interventional radiology procedures; and online medical bill payment services. As of December 31, 2020, the company operated 127 outpatient diagnostic imaging centers located in Florida, Texas, Pennsylvania, Delaware, Georgia, Illinois, and Kansas. Akumin Inc. is headquartered in Plantation, Florida.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-22 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

+5.67 (+1.18%)

USD70.20B 112.35 63.37
IDXX IDEXX Laboratories, Inc

+12.52 (+1.87%)

USD57.18B 86.28 64.42
DXCM DexCom, Inc

+3.91 (+0.87%)

USD43.23B 85.88 108.26
EXAS Exact Sciences Corporation

+0.26 (+0.22%)

USD20.20B N/A N/A
ICLR ICON Public Limited Company

-4.57 (-2.13%)

USD17.04B 33.71 35.96
GH Guardant Health, Inc

+0.23 (+0.19%)

USD12.08B N/A N/A
OZON Ozon Holdings PLC

+0.39 (+0.73%)

USD11.21B N/A N/A
PRAH PRA Health Sciences, Inc

N/A

USD10.70B 50.52 25.79
NTRA Natera, Inc

-0.27 (-0.23%)

USD10.30B N/A N/A
SYNH Syneos Health, Inc

+0.19 (+0.22%)

USD9.05B 46.76 22.95

ETFs Containing AKU

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.81% 45% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.81% 45% F 47% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.23B 31% F 34% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 72.00 36% F 16% F
Price/Book Ratio 1.65 98% A+ 68% D+
Price / Cash Flow Ratio 8.53 40% F 41% F
EV/EBITDA 24.27 55% F 37% F
Management Effectiveness  
Return on Equity -12.89% 63% D 45% F
Return on Invested Capital 7.31% 77% C+ 73% C
Return on Assets 2.03% 73% C 66% D
Debt to Equity Ratio 290.29% 8% F 6% F
Technical Ratios  
Short Ratio 0.19 100% A+ 92% A-
Short Percent 0.12% 100% A+ 94% A
Beta 1.34 44% F 37% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.